MedTrace Logo

Effects of a NeuroAD System, for the Treatment of Alzheimer Disease

NCT02166827 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-03-31

No results posted yet for this study

Summary

To evaluate the long-term efficacy of the NeuroAD system

Conditions

Interventions

DEVICE

NeuroAD

Synchronized TMS and cognitive stimulation to 6 brain areas.

DEVICE

Sham TMS+Cog

Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.

Sponsors & Collaborators

  • Neuronix Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166827 on ClinicalTrials.gov